Xgene Pharmaceutical

Biotech & Life Sciences · China · Founded 2016

Creating new, conjugated molecules that can be used to treat neurological disorders MoreLess

Xgene Pharmaceutical, Inc. is a late clinical stage, venture capital-backed international company specializing in the development of novel, multimodal, conjugated molecules aimed at treating neurological disorders. Utilizing proprietary linker technology, Xgene focuses on enhancing the efficacy and tolerability of pain therapeutics. The company serves the pharmaceutical and biotechnology sectors, targeting clients who require advanced therapeutic solutions for neurological conditions. Operating in the global market, Xgene's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through venture capital funding, partnerships, and future sales of approved therapies.

Keywords: linker technology, multimodal molecules, neurological disorders, pain therapeutics, venture capital, clinical stage, pharmaceutical, biotechnology, research and development, global market.

Valuation $100–500M

Total funding $50–100M

Unlock exact values

Company overview

Xgene Pharmaceutical company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2016
Headquarters: China
Employees: —
Open positions: None listed
Dealroom signal: 18.7

Website ↗

sub industryPharmaceuticalsub industryBioTechnologyindustryHealthsectorBiotechnologysectorBiotech and PharmasectorHard TechsectorDT and LSsectorscience-based

Valuation & funding

Xgene Pharmaceutical funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Aug 2022	—	—	Taiwania Capital	—
SERIES COther financing	Nov 2021	$40M	$160M	Ping An Ventures · Yijing Capital · Neovision Capital · GSR United Capital	—
SERIES BOther financing	Oct 2018	$20M	$80M	Ping An Ventures · TF Capital	—
SERIES AOther financing	Oct 2017	$0	—	TF Capital	—

Showing 4 recorded eventsUnlock the complete deal history →

Growth signals

Xgene Pharmaceutical website traffic

Latest recorded traffic for Xgene Pharmaceutical is 2.9K monthly website visits, up 81.3% over the last three months.

Latest monthly visits2.9K 3-month web change+81.3%

Monthly website visits51 observations · Apr 2020–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Xgene Pharmaceutical compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
SISPES Pharmaceuticals Inc.The company focuses on the research and development of improved specialty injectable products 505(b)(2)and complex generic drugs	United States	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational
VBVincere BiosciencesVincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD)	Cohasset, United States	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Xgene Pharmaceutical's talent

Book a demo to see the people

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Xgene Pharmaceutical's cap table

Sourced from Dealroom's funding and investor records.

Series A 3 investors entered at this stage

TF Capital

Ping An Ventures

Taiwania Capital

Series B+ 3 investors entered at this stage

Neovision Capital

Yijing Capital

GSR United Capital

Global footprint

Where Xgene Pharmaceutical has talent and traffic

Workforce by country

🇨🇳 China HQ

Book a demo for the full country breakdown

In the news

Latest news about Xgene Pharmaceutical

Recent press, funding announcements, and product moves mentioning Xgene Pharmaceutical — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Xgene Pharmaceutical

An AI-synthesized read of the highest-engagement posts about Xgene Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xgene Pharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.